Effect of Aldosterone Blockade on Arterial Compliance

The present study investigated the long-term (12 months) effect of spironolactone treatment on glucose homeostasis, metabolic parameters and vascular properties.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arterial Stiffness Arterial Elasticity

Age range

45 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Wolfson Medical Center

Holon, 58100, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with type 2 diabetes mellitus

Exclusion criteria

history of unstable angina, myocardial infarction (MI), cerebrovascular accident (CVA)
major surgery within the six months preceding entrance to the study
unbalanced endocrine disease
any disease that might affect absorption of medications
plasma creatinine >2.5 mg/dl
elevation of liver enzymes to more that twice the upper normal limit
plasma potassium levels >5.5 mg/dl

Treatment and study plan

Spironolactone

Drug

Spironolactone orally, at a dose of 50 mg/day for 12 months

Sponsors and collaborators

Lead sponsor

Wolfson Medical Center

Other Gov

Registry information

Official study title

Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance

Acronym: RAAS LAEI SAEI

Important dates

Study start: 2004
Primary completion: 2007
Study completion: 2007
First posted: Mar 18, 2010
Registry last updated: Mar 29, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed